JP2019504024A - 腎結石を治療する医薬製剤ならびにその製造方法および用法 - Google Patents

腎結石を治療する医薬製剤ならびにその製造方法および用法 Download PDF

Info

Publication number
JP2019504024A
JP2019504024A JP2018532419A JP2018532419A JP2019504024A JP 2019504024 A JP2019504024 A JP 2019504024A JP 2018532419 A JP2018532419 A JP 2018532419A JP 2018532419 A JP2018532419 A JP 2018532419A JP 2019504024 A JP2019504024 A JP 2019504024A
Authority
JP
Japan
Prior art keywords
composition
stone disease
component
reducing agent
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018532419A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019504024A5 (enExample
Inventor
イリアス サアデ，デニス
イリアス サアデ，デニス
ビッターマン，ジョゼフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harrow Inc
Original Assignee
Imprimis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imprimis Pharmaceuticals Inc filed Critical Imprimis Pharmaceuticals Inc
Publication of JP2019504024A publication Critical patent/JP2019504024A/ja
Publication of JP2019504024A5 publication Critical patent/JP2019504024A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018532419A 2015-12-22 2016-12-19 腎結石を治療する医薬製剤ならびにその製造方法および用法 Pending JP2019504024A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562271020P 2015-12-22 2015-12-22
US62/271,020 2015-12-22
US201562272894P 2015-12-30 2015-12-30
US62/272,894 2015-12-30
PCT/US2016/067466 WO2017112574A1 (en) 2015-12-22 2016-12-19 Pharmaceutical formulations for treating kidney stones and methods for fabricating and using thereof

Publications (2)

Publication Number Publication Date
JP2019504024A true JP2019504024A (ja) 2019-02-14
JP2019504024A5 JP2019504024A5 (enExample) 2020-02-06

Family

ID=59064032

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018532419A Pending JP2019504024A (ja) 2015-12-22 2016-12-19 腎結石を治療する医薬製剤ならびにその製造方法および用法

Country Status (7)

Country Link
US (1) US20170172960A1 (enExample)
EP (1) EP3393469A4 (enExample)
JP (1) JP2019504024A (enExample)
KR (1) KR20180095647A (enExample)
AU (1) AU2016378399A1 (enExample)
CA (1) CA3009332A1 (enExample)
WO (1) WO2017112574A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018285927B2 (en) * 2017-06-16 2023-04-20 Altibio, Inc. Modified-release tiopronin compositions, kits and methods for treating cystinuria and related disorders
US20190282525A1 (en) * 2018-03-19 2019-09-19 Cronus Research Labs Private Limited Tiopronin oral composition
WO2020092402A1 (en) * 2018-10-30 2020-05-07 Harrow Health, Inc. Pharmaceutical compositions of tiopronin and methods for preparing thereof
US20220016078A1 (en) * 2020-07-14 2022-01-20 GyanRx Sciences, Inc. Methods Of Treating Kidney Stones
US20240254098A1 (en) * 2021-05-10 2024-08-01 Altibio, Inc. Thioester prodrugs for the treatment of renal anomalies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050025839A1 (en) * 2003-07-28 2005-02-03 Polli James Edward Formulation approach to enhance transporter-mediated drug uptake
CN1833637A (zh) * 2005-03-16 2006-09-20 安徽龙科马生物制药有限责任公司 一种新的硫普罗宁冻干粉制剂及其制备方法
JP2013542975A (ja) * 2010-11-18 2013-11-28 アドビセンヌ クエン酸及び重炭酸塩を含んでなる医薬組成物、並びにシスチン尿症を治療するためのこれらの使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100361653C (zh) * 2004-09-29 2008-01-16 上海华源医药科技发展有限公司 硫普罗宁软胶囊
AR052225A1 (es) * 2004-11-04 2007-03-07 Astrazeneca Ab Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones
CN1698594A (zh) * 2005-04-25 2005-11-23 中国药科大学 硫普罗宁的缓释制剂
CN101062024B (zh) * 2006-04-25 2012-11-07 刘祥华 一种硫普罗宁组合药物及其制备方法
US8916609B2 (en) * 2011-06-10 2014-12-23 New York University Compounds as L-cystine crystallization inhibitors and uses thereof
CN102516143B (zh) * 2012-01-06 2013-11-20 刘全胜 一种硫普罗宁无菌粉及其制剂与制备方法
WO2014145195A1 (en) * 2013-03-15 2014-09-18 Cerovene, Inc. Pharmaceuticals comprising a ph-dependent component and ph-raising agent

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050025839A1 (en) * 2003-07-28 2005-02-03 Polli James Edward Formulation approach to enhance transporter-mediated drug uptake
CN1833637A (zh) * 2005-03-16 2006-09-20 安徽龙科马生物制药有限责任公司 一种新的硫普罗宁冻干粉制剂及其制备方法
JP2013542975A (ja) * 2010-11-18 2013-11-28 アドビセンヌ クエン酸及び重炭酸塩を含んでなる医薬組成物、並びにシスチン尿症を治療するためのこれらの使用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CLIN J AM SOC NEPHROL, vol. 10, JPN6020043290, July 2015 (2015-07-01), pages 1235 - 1245, ISSN: 0004521768 *
KIDNEY INTERNATIONAL, vol. 79, JPN6020043295, 2011, pages 385 - 392, ISSN: 0004384736 *
PEDIATR NEPHROL, vol. 22, JPN6020043291, 2007, pages 1869 - 1873, ISSN: 0004521769 *
UROL RES, vol. 29, JPN6020043293, 2001, pages 295 - 302, ISSN: 0004384735 *

Also Published As

Publication number Publication date
EP3393469A4 (en) 2019-09-25
CA3009332A1 (en) 2017-06-29
KR20180095647A (ko) 2018-08-27
WO2017112574A1 (en) 2017-06-29
US20170172960A1 (en) 2017-06-22
EP3393469A1 (en) 2018-10-31
AU2016378399A1 (en) 2018-06-28

Similar Documents

Publication Publication Date Title
CA2506930C (en) Dosage forms containing a proton pump inhibitor, a nsaid, and a buffer
EP1569692B1 (en) Betaine and salicylic acid compositions
JP2019504024A (ja) 腎結石を治療する医薬製剤ならびにその製造方法および用法
US20040131676A1 (en) Dosage forms containing a PPI, NSAID, and buffer
US20090075950A1 (en) Dosage Forms Containing A PPI, NSAID And A Buffer
JPS63290830A (ja) 胃腸疾患を治療するための組成物及び方法
CN101068535A (zh) 用于吸收含磷化合物的口服组合物
EP2043637A2 (en) Methods and medicaments for administration of ibuprofen
JPS62501845A (ja) 制御放出塩化カリウム
JPH01226810A (ja) 悪性腫瘍を破壊する作用を有する剤、その製造方法及び癌疾患の治療に使用する調製物
JP2022521233A (ja) 桂皮酸を含む組成物及びその使用方法
JP2013512930A (ja) ４−メチルピラゾール製剤
JP2020520996A (ja) フペルジンの放出調節医薬組成物およびその使用方法
DK165966B (da) Forbedret piroxicamholdigt anti-inflammatorisk praeparat
DK166343B (da) Forbedret piroxicamholdigt laegemiddel
RU2354378C1 (ru) Комбинированный противотуберкулезный препарат
RU2195937C1 (ru) Комбинированный противотуберкулезный препарат (ризобутол)
JPWO2007007757A1 (ja) ＰＰＡＲγアゴニストを含有する医薬組成物
JP2019011320A (ja) ペマフィブラートを含有する医薬
JPH05139964A (ja) 塩酸メキシレチン腸溶性製剤
WO2007041499A2 (en) Cox inhibitor and nicotinic acid compositions and methods
RU2468802C2 (ru) Комбинированная противотуберкулезная композиция
TWI538672B (zh) 應用二甲雙胍與丁酸鈉於ｋｒａｓ基因突變癌症治療之用途、醫藥組合物與醫藥套組
RU2201230C1 (ru) Лекарственное средство флузол, обладающее противогрибковым действием
JP6521968B2 (ja) 吸着ヨウ素および／または吸着ヨウ化物塩を含む活性炭とナトリウム／ヨウ化物共輸送体阻害剤とを含む肺機能を改善するための組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191218

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20200316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200316

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210608